secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2026-08-04T11:30:19+00:00
Accession:  0001193125-26-331556
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palvella reports Q2 net loss $21.9M; submits first NDA module for QTORIN rapamycin
--------------------------------------------------------------------------------

- Net loss $21.9M ($1.52/share) vs $9.5M ($0.86) in Q2 2025; R&D spend $12.5M (up from $5.1M).
- Cash, equivalents, and short-term investments $250.6M as of June 30, 2026.
- Submitted first module of rolling NDA for QTORIN rapamycin in microcystic lymphatic malformations; completion on track for H2 2026.
- Planned U.S. commercial launch in H1 2027 if approved; Phase 3 trial for cutaneous venous malformations planned for Q4 2026.
- Appointed Matt Pauls to Board; uplisted to Nasdaq Global Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000119312526331556/0001193125-26-331556-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000119312526331556/pvla-20260804.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-331556

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer